CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors

被引：0
|
作者：
Wang, S. [1 ,2 ]
Arribas, A. J. [3 ]
Tarantelli, C. [3 ]
Pradier, A. [1 ,2 ]
Zucca, E. [3 ]
Rossi, D. [3 ]
Simonetta, F. [1 ,2 ]
Bertoni, F. [3 ]
机构：
[1] Univ Geneva, Geneva Univ Hosp, Dept Oncol, Div Hematol, Geneva, Switzerland
[2] Translat Res Ctr Oncohaematol, Geneva, Switzerland
[3] USI, Fac Biomed Sci, Inst Oncol Res, Bellinzona, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
297
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [21] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [22] PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
    Tarantelli, Chiara
    Argnani, Lisa
    Zinzani, Pier Luigi
    Bertoni, Francesco
    CANCERS, 2021, 13 (21)
  • [23] Expansion of PD-1-Positive T-cells in Nodal Marginal Zone Lymphoma (MZL) - A Diagnostic Pitfall
    Egan, Caoimhe
    Laurent, Camille
    Kallen, Michael E.
    Pileri, Stefano
    Campo, Elias
    Swerdlow, Steven H.
    Piris, Miguel
    Chan, Wing C.
    Warnke, Roger
    Gascoyne, Randy
    Raffeld, Mark
    Pittaluga, Stefania
    Jaffe, Elaine S.
    LABORATORY INVESTIGATION, 2017, 97 : 346A - 346A
  • [24] Expansion of PD-1-Positive T-cells in Nodal Marginal Zone Lymphoma (MZL) A Diagnostic Pitfall
    Egan, Caoimhe
    Laurent, Camille
    Kallen, Michael E.
    Pileri, Stefano
    Campo, Elias
    Swerdlow, Steven H.
    Piris, Miguel
    Chan, Wing C.
    Warnke, Roger
    Gascoyne, Randy
    Raffeld, Mark
    Pittaluga, Stefania
    Jaffe, Elaine S.
    MODERN PATHOLOGY, 2017, 30 : 346A - 346A
  • [25] Effects of selective PI3Kδ inhibitors on activation and downstream signalling in T cells
    Bjorhall, K.
    Blomqvist, S. R.
    Yrlid, L.
    Gustavsson, M.
    Uddin, M.
    Holden, N.
    Karabelas, K.
    IMMUNOLOGY, 2014, 143 : 20 - 21
  • [26] Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K/AKT pathway
    de la Cruz, Ferran Fece
    Varkaris, Andreas
    Martin, Elizabeth E.
    Norden, Bryanna L.
    Chevalier, Nicholas
    Kehlmann, Allison M.
    Leshchiner, Ignaty
    Barnes, Haley
    Ehnstrom, Sara
    Patel, Parasvi
    Kim, Janice S.
    Ellis, Haley
    Sanidas, Ioannis
    Lau, Kayao T.
    Bardia, Aditya
    Spring, Laura M.
    Isakoff, Steven J.
    Lennerz, Jochen K.
    Getz, Gad
    Corcoran, Ryan B.
    Juric, Dejan
    CANCER RESEARCH, 2024, 84 (07)
  • [27] ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
    Arribas, Alberto J.
    Napoli, Sara
    Cascione, Luciano
    Barnabei, Laura
    Sartori, Giulio
    Cannas, Eleonora
    Gaudio, Eugenio
    Tarantelli, Chiara
    Mensah, Afua A.
    Spriano, Filippo
    Zucchetto, Antonella
    Rossi, Francesca M.
    Rinaldi, Andrea
    de Moura, Manuel Castro
    Stathis, Anastasios
    Stussi, Georg
    Gattei, Valter
    Brown, Jennifer R.
    Esteller, Manel
    Zucca, Emanuele
    Rossi, Davide
    Bertoni, Francesco
    CANCER RESEARCH, 2023, 83 (07)
  • [28] BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
    Kong, Weibo
    Sender, Sina
    Taher, Leila
    Villa-Perez, Simon
    Ma, Yixuan
    Sekora, Anett
    Ruetgen, Barbara C.
    Brenig, Bertram
    Beck, Julia
    Schuetz, Ekkehard
    Junghanss, Christian
    Nolte, Ingo
    Murua Escobar, Hugo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [29] Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
    Bhattacharya, Bhaskar
    Low, Sarah Hong Hui
    Chong, Mei Ling
    Chia, Dilys
    Koh, King Xin
    Sapari, Nur Sabrina
    Kaye, Stanley
    Huynh Hung
    Benoukraf, Touati
    Soong, Richie
    ONCOTARGET, 2016, 7 (20) : 29187 - 29198
  • [30] Overcoming acquired resistance to PI3K inhibitors in head and neck squamous cell carcinoma with combination treatment
    Mizrachi, Aviram
    Dunn, Lara
    Ho, Alan
    Scaltriti, Maurizio
    CLINICAL CANCER RESEARCH, 2017, 23 (23)
12345